Aureus Process and market Opportunity
R&D research budgets are expected to continue increasing over the next years and are expected to reach in 2010, $135 billion (vs. $58.8 billion in 2007, Source: Phrma). Within this R&D research spending, bioinformatics represents $5 billion. The global bioinformatics industry has grown at a double-digit growth rate in the past and is expected to follow the same pattern in the next four years. US remains the largest market in the world, but Asia-Pacific countries, particularly India and China, are witnessing the fastest growth and are anticipated to emerge as the dominating forces in future. Phenomenal development in information technology (IT) and the Internet have fuelled the growth of the bioinformatics industry. Patent protection and lack of standardization remain the biggest challenge for the bioinformatics industry.
Need for Knowledge Management Solutions: Over the past years, the number of new Molecular Entities approved by the FDA has been shrinking, while the R&D expenses increase. Pharmaceutical companies are looking for solutions to effectively reduce costs in R&D. IT driven research and simulation systems will help the industry increase innovation, reduce the attrition rates and cost, and address greater regulatory controls. Reducing the attrition rate is a key factor of effective R&D investment for pharmaceutical companies.
To effectively help the industry, Aureus brings a unique solution, transforming data into knowledge, and making it easier and faster for the scientists and researchers to have access to data immediately transformed into knowledge, and leave them to the biggest value added part of their research work. With Aureus solutions, researchers instead of having to go through the laborious and not reproducible bibliography queries and analysis, can use Aureus and have access in a few minutes to an amount of information they would have needed days or weeks to extract. In addition Aureus’s well organized experimental data are used frequently as the basis of simulation systems and other modeling applications which predict or validate key hypotheses in drug discovery and improve the decision support processes.
